U.S. Infrastructure Stock News

In August 2026, Enovis Corporation reported second-quarter 2026 results showing sales of US$582.78 million and a reduced net loss of US$1.19 million, while six-month sales reached US$1.17 billion with a smaller net loss of US$9.95 million compared with the prior year. At the same time, Enovis reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic revenue growth, underscoring management’s confidence in the business trajectory despite losses. We will...

Recent Share Performance Context Luckin Coffee (OTCPK:LKNC.Y) has drawn fresh attention after its recent price move, with the stock closing at $36.45 as of 17 August 2026 and showing mixed return patterns across different time frames. Over the past day, week and month, Luckin Coffee has recorded returns of 1.53%, 6.83% and 19.12% respectively. Over the past 3 months, the stock shows an 11.81% gain, while the past year reflects a 3.32% decline. See our latest analysis for Luckin Coffee. The...

Entergy stock has delivered very strong returns over the past three years, yet the current valuation signals are cautious, with the Dividend Discount Model (DDM) implying the shares trade at a premium to its estimated intrinsic value while the broader checks do not point to a clear bargain. Entergy has returned 151.5% over the past three years, which puts recent gains under the spotlight when judging whether the current price still offers an attractive entry point. Expectations for steady...

Erasca (ERAS) is back in focus after reporting second quarter 2026 results that showed a wider net loss, alongside the appointment of veteran oncology leader Charles S. Fuchs as president of research and development. See our latest analysis for Erasca. Erasca’s recent earnings release, shelf registration filing of up to US$112.344 million and the ongoing securities class action have all landed while the stock trades at US$18.10, with a 90 day share price return of 55.97% and a year to date...

Rhythm Pharmaceuticals (RYTM) stock is in focus after the company appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer on 17 August 2026, adding experienced leadership in rare disease drug development. See our latest analysis for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals has seen momentum build over 2026, with a 30 day share price return of 8.11% and a 90 day share price return of 27.15%, while the 1 year total shareholder return of 18.58% sits against a very large 5 year total...

Acuity Inc. has appointed Ruth Gratzke as President of Acuity Brands Lighting, effective 1 September 2026, bringing more than 25 years of leadership experience across industrial technology, smart infrastructure and electrical products, and she will report directly to CEO Neil Ashe. Her track record at Siemens in scaling complex smart infrastructure portfolios and advancing digital and energy-efficient solutions gives Acuity additional executive depth in areas closely linked to its lighting...

Recent commentary on Gartner (IT) has focused on stronger earnings estimates, consistent revenue growth, and solid free cash flow, along with an active share repurchase program that together appear to be shaping current investor attention. See our latest analysis for Gartner. Gartner's recent 1 month share price return of 29.87% and 90 day share price return of 14.90% contrast with a year to date share price decline of 23.19% and a 1 year total shareholder return decline of 25.04%. Together,...

Schrödinger (SDGR) is back in focus after reporting second quarter 2026 results that moved from a loss to a profit, along with a new agreement to deploy its Bunsen AI co-scientist with Bristol Myers Squibb. See our latest analysis for Schrödinger. At a share price of $17.67, Schrödinger has seen a 43.4% 90 day share price return and a 15.3% 30 day share price return, although the 1 year total shareholder return is down 8.9%. This suggests recent momentum has picked up following the move to...

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

ADMA Biologics (ADMA) stock is back in focus after the company reported second quarter 2026 results, highlighted by US$124.4 million in sales and US$37.82 million in net income, along with reaffirmed full year revenue guidance. See our latest analysis for ADMA Biologics. At a share price of US$9.54, ADMA Biologics has seen a 1 month share price return of 9.53% and a 3 month share price return of 11.45%. However, the year to date share price return is down 46.64%, while the 5 year total...

Recent coverage of BGC Group highlights its expanding global brokerage and financial technology platform, including the Fenics and FMX businesses and a new prediction markets partnership, alongside reported strength in revenue and earnings per share growth over the past two years. This combination of diversification across trading platforms and commentary about a potentially attractive valuation has drawn fresh attention to BGC’s investment case among institutional and retail...

Why Bitdeer Technologies Group’s Latest Earnings and Shelf Registration Matter Bitdeer Technologies Group (BTDR) has drawn fresh investor interest after reporting second quarter and first half 2026 results that combined higher sales with a wider net loss and loss per share. The update arrived alongside a new shelf registration covering equity, debt, warrants and units. This gives Bitdeer flexibility to raise capital in different ways. Together, these moves are now central to how investors...

Applied Optoelectronics, Inc. recently reported past second-quarter 2026 results showing sales of US$191.92 million versus US$102.95 million a year earlier, alongside a wider net loss of US$22.78 million, and issued third-quarter 2026 revenue guidance of US$255 million to US$290 million. Beyond the headline numbers, the company is expanding laser and automated U.S. manufacturing capacity to serve growing AI data center and co-packaged optics demand while discussing new projects with multiple...

Willis Towers Watson (WTW) stock is drawing fresh attention after the company appointed Jayne Bok as Head of Hong Kong and Macau, expanding her responsibilities while she continues as Head of Investments, Asia. See our latest analysis for Willis Towers Watson. The leadership change comes as Willis Towers Watson trades at US$327.90, with a 30 day share price return of 11.75% and a 90 day share price return of 29.07%. Its 3 year total shareholder return of 69.89% contrasts with a slightly...

Pitney Bowes was recently highlighted by Zacks with a Strong Buy rating and an A grade for Value, citing its lower Forward P/E and PEG ratios relative to industry averages as indicating potential undervaluation. This renewed analyst attention underscores how Pitney Bowes’ valuation metrics compare favorably with sector peers, potentially reshaping how investors assess its balance between risk and reward. Next, we’ll examine how Pitney Bowes’ Strong Buy rating and value-focused metrics...

Graham stock moves after contract wins, earnings update and guidance reaffirmation Graham (GHM) stock has been reacting to a cluster of recent company updates, including more than US$43 million in new defense contracts, first quarter fiscal 2027 results, and reaffirmed full year sales guidance. See our latest analysis for Graham. Graham’s recent contract awards, earnings update and reaffirmed guidance come after a period of strong share price momentum, with a 90 day share price return of...

JBT Marel (JBTM) has drawn investor attention after its latest quarterly report, which paired updated 2026 revenue and earnings guidance with a new share repurchase program and a $0.10 quarterly cash dividend declaration. See our latest analysis for JBT Marel. Even with the stronger second quarter update and fresh capital return plans, JBT Marel’s recent momentum has been weak, with the share price down 14.01% over the last 30 days and 23.48% year to date. The 3 year total shareholder return...

In August 2026, Ligand Pharmaceuticals reported past second-quarter 2026 results showing revenue of US$63.69 million and net income of US$48.51 million, with basic earnings per share from continuing operations of US$2.42, alongside stronger first-half results than the prior year. Importantly for longer-term watchers, Ligand also reaffirmed its 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring...

In August 2026, Illumina, Inc. completed a US$299.913 million offering of 4.950% senior unsecured notes due September 19, 2029 and put in place a new US$1.00 billion unsecured revolving credit facility maturing in 2031, replacing its prior 2023 arrangement. Together, the fresh bond issuance and expanded revolving credit capacity indicate Illumina is actively reshaping its funding mix to support future corporate needs and balance-sheet flexibility. Next, we’ll examine how Illumina’s expanded...

Special call puts American Financial Group back under the microscope American Financial Group (AFG) has moved back into focus after its August 4 earnings release and a special call on August 13, which updated investors on recent performance and business trends. See our latest analysis for American Financial Group. Against this backdrop of the August earnings release and special call, American Financial Group’s recent share price has edged higher, with a 30 day share price return of 2.61%,...

Texas Capital Bancshares (TCBI) is in focus after Texas Capital Bank Private Wealth Advisors and Texas Capital Funds Trust moved to shift two Texas focused ETFs from the New York Stock Exchange to the new Texas Stock Exchange. See our latest analysis for Texas Capital Bancshares. At a share price of $99.83, Texas Capital Bancshares has seen some recent pressure, with the 1 month share price return down 4.99%. However, the year to date share price return of 8.87% and 1 year total shareholder...

Earlier this week, Progress Software announced that Bridget Collins, a veteran technology leader with more than 30 years of enterprise IT, AI and cybersecurity experience, has been appointed Chief Information Officer reporting directly to CEO Yogesh Gupta to head its global IT and security organization. By giving Collins responsibility for advancing AI across internal operations, overseeing cybersecurity and supporting M&A integration, Progress is signaling a stronger emphasis on using...

Aveanna Healthcare Holdings Inc. recently reported past second-quarter 2026 results showing sales of US$670.48 million and net income of US$40.29 million, alongside modest impairment charges of US$145,000. Management also raised full-year revenue guidance to more than US$2.68 billion, signaling increased confidence in the company’s operating performance and demand backdrop. We’ll now examine how Aveanna’s raised full-year revenue guidance reshapes its existing investment narrative for...